Table 1.
Demographic, comorbidity and SLE disease characteristics and therapies of patients.
| All Patients (n = 114) | OFs (n = 96) | IAFs (n = 38) | |
|---|---|---|---|
| Demographics | |||
| Women: n (%) | 100 (88) | 85 (88) | 33 (87) |
| Age at disease onset (years): median (IQR) | 28 (20–36) | 29 (20–37) | 26 (20–37) |
| Age at time of flare (years): median (IQR) | 44 (35–52) | 44 (35–52) | 32 (34–54) |
| Follow-up duration at time of flare (months): median (IQR) | 30 (13–62) | 34 (15–71) | 22(12–43) |
| General clinical characteristics (history): n (%) | |||
| Musculoskeletal involvement | 93 (80) | 78 (81) | 30 (79) |
| Mucocutaneous involvement | 82 (81) | 70 (72) | 26 (68) |
| Renal involvement | 47 (40) | 38 (39) | 17 (44) |
| NPSLE | 28 (24) | 22 (22) | 10 (26) |
| Cardiopulmonary involvement | 14 (12) | 9 (9) | 6 (15) |
| Haematological manifestations | 94 (82) | 78 (81) | 30 (79) |
| Constitutional symptoms | 46 (40) | 38 (39) | 17 (45) |
| Gastrointestinal manifestations | 1 (1) | 1 (1) | 0 (0) |
| Anti-phospholipid syndrome | 11 (10) | 9 (9) | 6 (16) |
| Serology (history): n (%) | |||
| Anti-dsDNA | 85 (74) | 71 (74) | 30 (79) |
| Anti-Sm | 30 (26) | 24 (25) | 10 (26) |
| Low complement (C3 and/or C4) | 31 (27) | 27 (28) | 11 (29) |
| Antiphospholipid antibodies | |||
|
35 (30) | 29 (30) | 13 (34) |
|
18 (16) | 18 (18) | 7 (18) |
|
23 (20) | 20 (1) | 8 (21) |
NPSLE: neuropsychiatric systemic lupus erythematosus; LAC: lupus anticoagulant.